High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients

Pancreas

Volumn 38, Issue 2, 2009, Pages 154-160

  Sanlioglu, Ahter Dilsad ^a,c   Dirice, Ercument ^a   Elpek, Ozlem ^b   Korcum, Aylin Fidan ^b   Ozdogan, Mustafa ^c   Suleymanlar, Inci ^c   Balci, Mustafa Kemal ^c   Griffith, Thomas S ^d   Sanlioglu, Salih ^a,c  

^a Human Gene Therapy Unit   (Turkey)

^b Department of Pathology ^*

^c AKDENIZ UNIVERSITY   (Turkey)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

TRAIL, pancreas, ductal adenocarcinoma, cell death

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; LIPOCORTIN 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TNFRSF10A PROTEIN, HUMAN; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACINAR CELL; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CELL DEATH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LYMPH NODE METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS CELL; PANCREAS ISLET CELL; PANCREAS NECROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SCHOOL CHILD; UPREGULATION; ADENOCARCINOMA; CHEMISTRY; MIDDLE AGED; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; ISLETS OF LANGERHANS; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 65349134138     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31818db9e3     Document Type: Article

References (41)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
3. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057.
4. Warshaw AL, Gu ZY, Wittenberg J, et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg. 1990;125:230-233.
5. Howard TJ. Pancreatic adenocarcinoma. Curr Probl Cancer. 1996;20:281-328.
6. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer. 1996;78:580-591.
7. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
8. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355-366; discussion 366-358.
9. Sanlioglu AD, Griffith TS, Omer A, et al. Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem. 2008;104:710-720.
10. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563.
11. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999;162:2597-2605.
12. Griffith TS, Anderson RD, Davidson BL, et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000;165:2886-2894.
13. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163.
14. Terzioglu E, Bisgin A, Sanlioglu AD, et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46:783-789.
15. Katz MH, Spivack DE, Takimoto S, et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol. 2003;10:762-772.
16. Jacob D, Davis JJ, Zhang L, et al. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 2005;12:109-115.
17. Abe K, Kurakin A, Mohseni-Maybodi M, et al. The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Acad Sci. 2000;926:52 -63.
18. Karacay B, Sanlioglu S, Griffith TS, et al. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther. 2004;11:681-690.
19. Sanlioglu AD, Koksal T, Baykara M, et al. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Gene Ther Mol Biol. 2003;7:113-133.
20. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas. 2001;23:72-79.
21. Sanlioglu AD, Dirice E, Aydin C, et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005;5:54.
22. Sanlioglu AD, Koksal IT, Karacay B, et al. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther. 2006;13:21-31.
23. Aydin C, Sanlioglu AD, Karacay B, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther. 2007;18:39-50.
24. Sanlioglu AD, Karacay B, Koksal IT, et al. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther. 2007;14:976-984.
25. Liao Q, Friess H, Kleeff J, et al. Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res. 2001;21:3153-3159.
26. Bai J, Sui J, Demirjian A, et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factorYrelated apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005;65:2344-2352.
27. Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther. 2006;5:2251-2260.
28. Chu GC, Kimmelman AC, Hezel AF, et al. Stromal biology of pancreatic cancer. J Cell Biochem. 2007.
29. Wagner M, Kleeff J, Friess H, et al. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas. 1999;19:370-376.
30. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 1998;383:129-133.
31. Sanlioglu AD, Dirice E, Elpek O, et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas. 2008;36:385-393.
32. Sanlioglu AD, Koksal IT, Ciftcioglu A, et al. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol. 2007;177:359-364.
33. Koksal IT, Sanlioglu AD, Karacay B, et al. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol. 2008;26:158-165.
34. Sanlioglu AD, Korcum AF, Pestereli E, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:716-723.
35. Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene. 2001;20:4258-4269.
36. Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001;23:251-258.
37. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163:71-81.
38. Trauzold A, Siegmund D, Schniewind B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25:7434-7439.
39. Cheung SS, Metzger DL, Wang X, et al. Tumor necrosis factor-related apoptosis-inducing ligand and CD56 expression in patients with type 1 diabetes mellitus. Pancreas. 2005;30:105-114.
40. Ou D, Metzger DL, Wang X, et al. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia. 2002;45:1678-1688.
41. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.